MA56550A - Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparation - Google Patents

Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparation

Info

Publication number
MA56550A
MA56550A MA056550A MA56550A MA56550A MA 56550 A MA56550 A MA 56550A MA 056550 A MA056550 A MA 056550A MA 56550 A MA56550 A MA 56550A MA 56550 A MA56550 A MA 56550A
Authority
MA
Morocco
Prior art keywords
diazaspiro
octane
carboxylate
oxo
tert
Prior art date
Application number
MA056550A
Other languages
English (en)
French (fr)
Inventor
Danny T Ding
Shaoxin Feng
William R Perrault
Xiaoda Yuan
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of MA56550A publication Critical patent/MA56550A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA056550A 2019-06-24 2020-06-23 Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparation MA56550A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962865826P 2019-06-24 2019-06-24

Publications (1)

Publication Number Publication Date
MA56550A true MA56550A (fr) 2022-04-27

Family

ID=74060350

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056550A MA56550A (fr) 2019-06-24 2020-06-23 Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparation

Country Status (11)

Country Link
US (1) US20220267341A1 (enExample)
EP (1) EP3986399A4 (enExample)
JP (2) JP7617043B2 (enExample)
CN (1) CN114364380A (enExample)
AU (1) AU2020304001B2 (enExample)
BR (1) BR112021026380A2 (enExample)
CA (1) CA3144600A1 (enExample)
IL (1) IL289198A (enExample)
MA (1) MA56550A (enExample)
MX (2) MX2022000069A (enExample)
WO (1) WO2020263847A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4484431A3 (en) * 2019-06-24 2025-03-26 Naurex Inc. Processes and intermediates for producing diazaspiro lactam compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
ES2416354T3 (es) * 2005-06-21 2013-07-31 Ajinomoto Co., Inc. Cristal de derivado de fenilalanina, método de producción del mismo y uso del mismo
BRPI0918868B8 (pt) * 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
US9758525B2 (en) * 2013-01-29 2017-09-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
PE20151416A1 (es) * 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
DK3436463T3 (da) * 2016-03-28 2021-08-30 Takeda Pharmaceuticals Co Krystalline former af 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-on hemi-hydrat
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
EP4484431A3 (en) * 2019-06-24 2025-03-26 Naurex Inc. Processes and intermediates for producing diazaspiro lactam compounds

Also Published As

Publication number Publication date
WO2020263847A1 (en) 2020-12-30
AU2020304001B2 (en) 2026-04-09
JP2025069143A (ja) 2025-04-30
MX2022000069A (es) 2022-05-24
US20220267341A1 (en) 2022-08-25
KR20220061088A (ko) 2022-05-12
CA3144600A1 (en) 2020-12-30
EP3986399A4 (en) 2023-06-07
JP7617043B2 (ja) 2025-01-17
JP2022539342A (ja) 2022-09-08
IL289198A (en) 2022-02-01
AU2020304001A1 (en) 2022-01-27
CN114364380A (zh) 2022-04-15
MX2025002579A (es) 2025-04-02
BR112021026380A2 (pt) 2022-05-10
EP3986399A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
EP3934652A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
EP3980046A4 (en) KRAS G12V MUTANT THAT BINDS TO JAK1, INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS
MX2019013954A (es) Inhibidores covalentes de kras.
EP3914651A4 (en) CARBONATE AGGREGATE COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION AND USE
EP3504196A4 (en) METHOD FOR PRODUCING OLAPARIB
MX2020009290A (es) Inhibidores de la arginasa.
WO2007027527A3 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
WO2016164675A8 (en) Substituted quinazoline compounds and methods of use thereof
WO2015200680A8 (en) Prmt5 inhibitors and uses thereof
EP3893655A4 (en) METHOD OF PREPARING A PLANT PROTEIN COMPOSITION
MX380928B (es) Inhibidores de kras g12c.
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
EP3359159A4 (en) PHARMACEUTICAL SALTS, PHYSICAL FORMS AND COMPOSITIONS OF PYRROLOPYRIMIDINE KINASE INHIBITORS AND METHOD FOR THE PRODUCTION THEREOF
EP3773900A4 (en) HINOKITIOL ANALOGUES, PROCESSES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
EP3969457A4 (en) PROCESS FOR THE PRODUCTION OF MACROCYCLIC INDOLES
PH12018500653B1 (en) Salts and solid forms of monobactam antibiotic
MA53427B1 (fr) Inhibiteurs de l'arginase et leurs méthodes d'utilisation
MA56132A (fr) Procédés de purification d'anticorps et compositions associées
EP3986399A4 (en) SOLID FORMS OF TERT-BUTYL (S)-2-((2S,3R)-1-AMINO-3-HYDROXY-1-OXOBU TAN-2-YL)-1-OXO-2,5-DIAZASPIRO[3.4]OCTANE E-5-CARBOXYLATE AND PROCESS OF PRODUCTION
WO2017095950A3 (en) Compounds for treating proliferative diseases
MA50862A (fr) Procédés de réduction des effets secondaires d'une thérapie par conjugués médicament anticorps anti-cd30
EP4031130A4 (en) COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS
EP3921322A4 (en) PHOSPHORUS-IMIDAZOCHINOLINE-AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF
EP4031567A4 (en) METHODS AND COMPOSITIONS FOR TISSUE REGENERATION
MA53603A (fr) Procédés de modulation de la cytotoxicité à médiation cellulaire dépendante des anticorps